139481-33-7

Usage

Uses

Used in Pharmaceutical Industry:
Azilsartan iMpurity I is used as an impurity in the manufacturing process of Azilsartan, an analgesic and anti-inflammatory drug. Its presence is crucial for ensuring the quality and safety of the final drug product, as it helps in monitoring and controlling the purity of the active pharmaceutical ingredient (API).
Azilsartan iMpurity I is used as a reference material for the development and validation of analytical methods, such as high-performance liquid chromatography (HPLC) and other chromatographic techniques. This helps in the accurate quantification and identification of the impurity in the drug product, ensuring compliance with regulatory guidelines and maintaining the overall quality of the medication.
Additionally, Azilsartan iMpurity I can be used in research and development for the study of the pharmacological effects and potential interactions of the impurity with the main API, Azilsartan. This information can be valuable in understanding the overall safety profile and efficacy of the drug, as well as in the development of new drug formulations or alternative treatments for hypertension and related conditions.

Upstream product

• 139481-35-9 methyl 2-<<(2'-cyanobiphenyl-4-yl)methyl>amino>-3-<(methoxycarbonyl)amino>benzoate 
• 139481-44-0 methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-benzimidazole-7-carboxylate 
• 139481-41-7 ethyl 1-[(2'-cyano-[1,1']-biphenyl-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate 
• 57113-90-3 methyl 2-(N-tert-butoxycarbonylamino)-3-nitrobenzoate 
• 603-11-2 3-nitrophthalic acid 
• 73833-13-3 acid chloride of 1-methylhydrogen-3-nitrophthalate 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 
• 139481-38-2 methyl 2-amino>-3-nitrobenzoate 
• 139481-28-0 methyl 2-<<2'-cyanobiphenyl-4-yl)methyl>amino>-3-nitrobenzoate 
• 136304-78-4 methyl 3-amino-2-[[(2'-cyanobiphenyl-4-yl)methyl]amino]benzoate 
• 856414-36-3 2-Azidocarbonyl-3-nitro-benzoic acid methyl ester 

Downstream Products

• 1499167-72-4 methyl 3-((2'-(N'-hydroxycarbamimidoyl)biphenyl-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate 
• 139481-97-3 2-Morpholin-4-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-98-4 2-Piperidin-1-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-51-9 methyl 1-<(2'-cyanobiphenyl-4-yl)methyl>-2-morpholino-1H-benzimidazole-7-carboxylate 
• 139481-52-0 methyl 1-<(2'-cyanobiphenyl-4-yl)methyl>-2-piperidino-1H-benzimidazole-7-carboxylate 
• 139481-34-8 methyl 2-chloro-1-<(2'-cyanobiphenyl-4-yl)methyl>-1H-benzimidazole-7-carboxylate 

Relevant academic research and scientific papers

A [...] process impurity D synthetic method

The invention discloses a process of impurity D [...] synthetic method. To methyl [...] A1 as raw materials, under acidic conditions to produce intermediate de-ethyl A2, intermediate A2 through hydrolysis to produce intermediate A3, A3 and then with hydro

Synthesis of azilsartan and its selected potential impurities

Synthesis of angiotensin II AT1 receptor antagonist azilsartan is described. The results include reinvestigation of the described process as well as its novel modification. This new process includes transformation of the CN group into amidoxime moiety by aqueous hydroxylamine, its treatment with alkyl chloroformates and a base-initiated cyclization of the formed (alkoxycarbonyl-oxy)carbamimidoyl intermediates. Several so far undescribed side-products were identified and some of them were synthesized and duly characterized as potential impurities.

A METHOD OF MANUFACTURING 2-ETHOXY-1-((2'-((HYDROXYAMINO) IMINOMETHYL)BIPHENYL-4- YL)METHYL)-1H-BENZO [D] IMIDAZOLE-7-CARBOXYLIC ACID AND ITS ESTERS

A method of manufacturing 2-ethoxy-1 -((2'-((hydroxyamino)iminomethyl)biphenyl-4- yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid and its esters of formula I, wherein R is either H or an (un)branched C1-C4 alkyl, ArCH2, Ar2CH, or Ar3C, wherein Ar is a (un)substituted phenyl, the key intermediates for the synthesis of azilsartan, the reaction of the corresponding nitrile of formula IV being carried out with aqueous hydroxylamine in a polar aprotic solvent, or in a mixture of such solvents.

Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazolecarboxylic Acids

A series of 2-substituted-1--1H-benzimidazole-7-carboxylic acids was prepared from the key intermediate 3-amino-2-amino>benzoate (6a-c) in order to clarify the structure-activity relationships of various analogues of 2-butyl-1-methyl>-1H-benzimidazole-7-carboxylic acid (CV-11194), a potent and long acting angiotensin II (AII) receptor antagonist.The AII antagonistic activity of the benzimidazoles was investigated by in vitro assays, which included an AII receptor binding assay and AII-induced vasocontraction assay, as well as by in vivo assays such as an AII-induced pressor response in rats.Most of the benzimidazoles showed high affinity for the AII receptor (IC50 value, 10-6-1--7 M) and inhibited the AII-induced pressor response at 1 or 3 mg/kg po, and the effects were more potent than those of CV-11194 and DuP 753.The structure-activity relationship studies on the binding affinity and the inhibition of AII-induced pressor response suggested that straight chains of a certain length (e.g., ethoxy groups, ethyl groups) were the best as substituents at the 2-position and that their steric factors, lipohilicity, and electronic effects affected the potency of the AII antagonistic action.Both a carboxyl group at the 7-position and a tetrazole ring at the 2'-position were particularly important for potent and orally active AII antagonistic activity and a long-acting hypotensive effect.The representative compound, 2-ethoxy-1-methyl>-1H-benzimidazole-7-carboxylic acid (26b, CV-11974), inhibited the specific binding of AII to bovine adrenal cortical membrane with an IC50 value of 1.1*10-7 M.The AII-induced contraction of rabbit aortic strips was antagonized by CV-11974 (IC50 value, 3.0*1--10 M).Oral administration of CV-11974 to conscious normatensive rats at 1 mg/kg resulted in long-lasting inhibition of the AII-induced pressor response.CV-11974 at 0.1-1 mg/kg iv reduced blood pressure dose-dependently in spontaneously hypertensive rats.